Therapeutic advances in endocrinology and metabolism
Cure8 research brief
Why This Matters
People with IBD increasingly also have obesity and type 2 diabetes; this commentary suggests GLP-1 receptor agonists might affect not only metabolism but also inflammation and clinical outcomes relevant to IBD, which could influence treatment conversations and research priorities.
Who Should Pay Attention
Adults with IBD and type 2 diabetes, endocrinologists, gastroenterologists, clinical researchers designing trials, and clinicians managing combined metabolic and IBD care.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The piece is an expert commentary/overview rather than a clinical trial report. It summarizes existing observational data and mechanistic links between GLP-1 therapies and inflammation, and highlights the need for carefully designed prospective studies in patients with IBD and type 2 diabetes.
Practical takeaways: If you have IBD and diabetes, this article suggests emerging evidence that GLP-1 receptor agonists may have neutral-to-possibly-beneficial effects on inflammation and healthcare utilization, but definitive randomized trial data are not yet available.
Decisions about diabetes medications should be made with your gastroenterologist and diabetes clinician. Tone and limits: The source is an editorial/abstract summarizing observations and rationale for research rather than providing new trial results.
Keep In Mind
This is an editorial/abstract (Therapeutic Advances in Endocrinology and Metabolism) summarizing observational data and mechanistic rationale. It does not report randomized trial results; authors call for prospective trials to confirm safety and benefit in IBD populations.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationTherapeutic advances in endocrinology and metabolism
AuthorsDured Dardari
InstitutionDiabetology Department, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France.
Study typeEditorial
Indexed viaPubMed
Source typeResearch paper
PublishedAug 26, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Letter: Upadacitinib in Perianal Crohn's Disease: Does Clinical Closure Reflect True Remission? Authors' Reply.
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from Alimentary pharmacology &...
Editorial: Risankizumab in Refractory Crohn's Disease-From Real-World Effectiveness to Strategic Positioning and Early Monitoring.
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from Alimentary pharmacology &...
Beyond mood: the neurobiological rationale for using SSRIs and SNRIs in the care of inflammatory bowel disease and disorders of gut-brain interaction.
This review suggests SSRIs and SNRIs may influence both brain and gut pathways relevant to symptom burden in IBD and DGBI — potentially improving mood, pain, motility, and aspects of inflammation. That could matter for...